美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

艾格里房產

75.04

+0.54000.72%

盤後：75.330.2900+0.39%16:34 EDT

成交量：100.29萬

成交額：7,506.35萬

市值：82.40億

市盈率：42.43

高：75.31

開：74.76

低：74.21

收：74.50

資料載入中...

總覽公司新聞公告

麗珠集團：已終止HER2-ADC項目後續推進，聚焦優勢項目研發進展

一款重磅ADC藥物上市申請延遲樂普生物股價大跌逾10%

一款重磅ADC藥物上市申請延遲，樂普生物股價大跌逾10%

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Nuvation Bio Inc.盤中異動股價大漲7.36%

金十數據整理：每日美股市場要聞速遞（3月3日週一）

SharkNinja, Inc. ：有望進一步驗證基本面“線性外推”邏輯 | 興·研究

第一三共/阿斯利康(AZN.US)重磅ADC療法有望再獲歐盟批准

【百利天恆：BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌 III 期臨牀試驗完成首例受試者入組】金融界3月2日消息，百利天恆自主研發的創新生物藥注射用 BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌的 III 期臨牀試驗已於近日完成首例受試者入組。BL-B01D1 是全球獨家處於 III 期註冊臨牀試驗階段的可同時靶向 EGFR 和 HER3 的雙抗 ADC 藥物。截至目前，BL-B01D1 正在中國和美國進行約 30 項針對多種腫瘤類型的臨牀試驗，除本次新入組的臨牀試驗外，其在肺癌、乳腺癌、鼻咽癌、食管鱗癌等 7 項國內 III 期註冊臨牀試驗也處於受試者入組階段。藥品需完成臨牀試驗並通過審評審批方可上市銷售，且醫藥產品具有高科技、高風險等特點，容易受到不確定性因素影響。

277億元！A股“醫藥一哥”2024年業績大增55%

映恩生物二次遞表港交所，致力於癌症及免疫性疾病的ADC藥物研發

HER2雙抗ADC藥物JSKN003治療HER2陽性乳腺癌Ⅲ期臨牀研究完成首例患者給藥

【首個自研ADC澳洲臨牀入組康方生物IO 2+ADC戰略再進一步】近日，康方生物宣佈，公司自主研發的差異化靶向人表皮生長因子受體3（HER3）ADC新藥AK138D1，治療晚期惡性腫瘤的I期臨牀研究在澳洲完成首例受試者入組。AK138D1是康方生物首個進入臨牀階段的ADC藥物。ADC藥物是康方生物在全球範圍內重塑治療格局，構建腫瘤治療新標準，以創新療法造福全球患者的重要力量，也是康方生物推進“IO 2.0+ADC”戰略的重要抓手。目前康方生物自主研發的全球首創雙抗新藥卡度尼利（PD-1/CTLA-4雙抗）和依沃西（PD-1/VEGF雙抗）均已獲批上市。康方生物是全球唯一擁有2個腫瘤免疫治療雙抗的製藥公司，在IO+ADC聯合戰略中已經建立了在腫瘤免疫端的全球領先優勢。AK138D1等差異化ADC藥物的開發，為康方生物充分挖掘創新產品組合的臨牀價值，持續迭代腫瘤療法開拓了更廣闊的空間。

金十數據整理：每日港股市場要聞速遞（2月26日週三）

康方生物依沃西攜手輝瑞ADC，國際化佈局提速

【券商聚焦】交銀國際維持康方生物(09926)買入評級指PD-1雙抗+ADC聯用潛力值得期待

Nuvation Bio Inc.盤中異動股價大跌5.29%報1.97美元

藥明合聯與LigaChem Biosciences簽署合作備忘錄，加速ADC開發

一款明星HER-2 ADC夢碎時

Nuvation Bio Inc.盤中異動急速下跌5.20%報2.10美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ADC/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房產","latestPrice":75.04,"timestamp":1748030400000,"preClose":74.5,"halted":0,"volume":1002913,"hourTrading":{"tag":"盘后","latestPrice":75.33,"preClose":75.04,"latestTime":"16:34 EDT","volume":13110,"amount":983828.62,"timestamp":1748032465719},"delay":0,"floatShares":107727624,"shares":109806548,"eps":1.768583,"marketStatus":"休市中","change":0.54,"latestTime":"05-23 16:00:00 EDT","open":74.76,"high":75.31,"low":74.21,"amount":75063454.73759,"amplitude":0.014765,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.768583,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1748332800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":74.5,"dividendRate":0.040219,"preHourTrading":{"tag":"盘前","latestPrice":74.31,"preClose":74.5,"latestTime":"09:25 EDT","volume":44,"amount":3276.04464,"timestamp":1748006705583},"postHourTrading":{"tag":"盘后","latestPrice":75.33,"preClose":75.04,"latestTime":"16:34 EDT","volume":13110,"amount":983828.62,"timestamp":1748032465719},"volumeRatio":1.0031259929424552,"impliedVol":0.2259,"impliedVolPercentile":0.636},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":107727624,"roa":"2.30%","roe":"3.55%","lyrEps":1.793039,"volumeRatio":1.0031259929424552,"shares":109806548,"dividePrice":3.018,"high":75.31,"amplitude":0.014765,"preClose":74.5,"low":74.21,"week52Low":58.52,"pbRate":"1.51","psRate":"12.94","week52High":79.65,"institutionHeld":0.8991,"latestPrice":75.04,"eps":1.768583,"divideRate":0.040219,"volume":1002913,"delay":0,"ttmEps":1.768583,"open":74.76,"prevYearClose":70.45,"prevWeekClose":74.92,"prevMonthClose":77.61,"prevQuarterClose":77.19,"fiveDayClose":74.92,"twentyDayClose":75.67,"sixtyDayClose":73.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516762936","title":"麗珠集團：已終止HER2-ADC項目後續推進，聚焦優勢項目研發進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2516762936","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516762936?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 18:09","pubTimestamp":1741082976,"startTime":"0","endTime":"0","summary":"金融界3月4日消息，有投资者在互动平台向丽珠集团提问：贵司与烟台迈百瑞，2016年达成协议共同开发ADC药物。还有在继续开发ADC药物吗？有无实质进展？公司回答表示：基于HER2-ADC项目的市场前景和竞争格局的综合考量，公司已终止该项目后续推进。目前公司生物药平台已建立抗体类药物、重组蛋白药物、重组蛋白疫苗等特色技术平台，未来将合理配置资源，进一步聚焦优势项目的研发进展。\n\n\r\n            责任编辑：安东","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04180948515547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK4080","ADC","000513","BK0188","BK0028","BK4231","BK0187"],"gpt_icon":0},{"id":"2516690588","title":"一款重磅ADC藥物上市申請延遲 樂普生物股價大跌逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690588","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690588?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:35","pubTimestamp":1741055751,"startTime":"0","endTime":"0","summary":"【一款重磅ADC药物上市申请延迟 乐普生物股价大跌逾10%】2025年3月3日，国家药监局网站公布当日药品通知件送达信息，乐普生物（02157.HK）的维贝柯妥塔单抗（MRG003）名列其中。这意味着，该款药物的上市申请暂未成功获批。公司于3月4日早间回应称，为补充提交相关资料，公司主动撤回前次MRG003的NDA（新药上市申请）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335794853.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335794853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK1161","02157","BK4231","BK4080"],"gpt_icon":0},{"id":"2516697428","title":"一款重磅ADC藥物上市申請延遲，樂普生物股價大跌逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516697428","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516697428?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:35","pubTimestamp":1741055714,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["02157","BK1161","BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2516966906","title":"FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516966906","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516966906?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 05:45","pubTimestamp":1741038300,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, March  03, 2025  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3036080/33525/en/FibroGen-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","FGEN","BK4139","BK4080","BK4505","BK4231"],"gpt_icon":0},{"id":"2516634779","title":"Nuvation Bio Inc.盤中異動 股價大漲7.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634779?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 22:32","pubTimestamp":1741012326,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Nuvation Bio Inc.股票出现波动，股价快速上涨7.36%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.23%、24.93%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为16.17%、9.55%、9.35%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223206abe63359&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223206abe63359&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4212","BK4007","DDC","ADC","NUVB","BK4080","BK4231"],"gpt_icon":0},{"id":"2516639334","title":"金十數據整理：每日美股市場要聞速遞（3月3日 週一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639334","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516639334?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 21:54","pubTimestamp":1741010095,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BTCO","BRRR","JNJ","BTCW","BITO","BABA","APT.USD.CC","USDT.USD.CC","HODL","ADC","BTC.USD.CC","AZN","NVDA","AAPL","TON.USD.HKCC","XPEV","AVAX.USD.HKCC","ARKK","LDO.USD.HKCC","SNX.USD.HKCC","ALGM","LTC.USD.HKCC","09042","161631","ON","03042","BTC.USD.HKCC","DEFI","03008","AMD","09868","APT.USD.HKCC","SNX.USD.CC","EZBC","MKR.USD.CC","AVAX.USD.CC","FBTC","TSLA","COMP.USD.HKCC","AVGO","ATOM.USD.HKCC","GFS","UNI.USD.HKCC","VBTC.AU","MSTU","09439","DOT.USD.HKCC","159813","GBTC"],"gpt_icon":1},{"id":"2516702805","title":"SharkNinja, Inc.  ：有望進一步驗證基本面“線性外推”邏輯 | 興·研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2516702805","media":"华兴证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516702805?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 14:02","pubTimestamp":1740981769,"startTime":"0","endTime":"0","summary":"SharkNinja,Inc.有望进一步验证基本面“线性外推”逻辑推新成功率优异，有望进一步验证基本面“线性外推”逻辑；当前估值依旧颇具风险收益比，但短期大概率延续区间震荡交易。报告名称：《SharkNinja,Inc.-有望进一步验证基本面“线性外推”逻辑》报告日期：2025年2月25日报告作者：姜雪烽, 分析师 | 执业证书编号:S1680519070001李宁维持预测，预计2024年营收/利润端分别+2.2%/-3.3%我们预计4Q24经营表现符合预期；我们预计2024年营收/归母净利润分别同比+2.2%/-3.3%至282.2/30.8亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303143601abe58b6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303143601abe58b6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","ASH","ADC","BK4231","BK4161","SN","BK4191","LU2242644610.SGD","CR","BK4109","LU2463526074.USD"],"gpt_icon":0},{"id":"2516578625","title":"第一三共/阿斯利康(AZN.US)重磅ADC療法有望再獲歐盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516578625","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516578625?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 10:46","pubTimestamp":1740969968,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，日前，第一三共与阿斯利康共同宣布，其联合开发的重磅抗体偶联药物Enhertu获得欧洲药品管理局人用药品委员会推荐在欧盟获批，作为单药用于治疗不可切除或转移性激素受体阳性、HER2低表达或HER2极低表达的乳腺癌成人患者，这些患者至少接受过一种内分泌疗法治疗转移性癌症，且被认为不适合接受内分泌疗法作为下一线治疗。据悉，Enhertu是首款具有不限癌种适应症的HER2靶向ADC疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4080","ADC","AZN","BK4231","LU2456880835.USD","LU0320765992.SGD","LU2417539215.USD","LU2236285917.USD","LU0109394709.USD","BK4568","BK4585","LU1829250122.USD","LU2462157665.USD","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2516364590","title":"【百利天恆：BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌 III 期臨牀試驗完成首例受試者入組】金融界3月2日消息，百利天恆自主研發的創新生物藥注射用 BL-B01D1（EGFR×HER3 雙抗 ADC）聯合奧希替尼用於一線 EGFR 突變型局部晚期或轉移性非小細胞肺癌的 III 期臨牀試驗已於近日完成首例受試者入組。BL-B01D1 是全球獨家處於 III 期註冊臨牀試驗階段的可同時靶向 EGFR 和 HER3 的雙抗 ADC 藥物。截至目前，BL-B01D1 正在中國和美國進行約 30 項針對多種腫瘤類型的臨牀試驗，除本次新入組的臨牀試驗外，其在肺癌、乳腺癌、鼻咽癌、食管鱗癌等 7 項國內 III 期註冊臨牀試驗也處於受試者入組階段。藥品需完成臨牀試驗並通過審評審批方可上市銷售，且醫藥產品具有高科技、高風險等特點，容易受到不確定性因素影響。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364590","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364590?lang=zh_tw&edition=fundamental","pubTime":"2025-03-02 15:34","pubTimestamp":1740900843,"startTime":"0","endTime":"0","summary":"金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1 联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/02153448475153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4231","BK1141","LU0757428866.USD","BK1576","BK4023","03347","688506","09939","BK4134","BK0239","BK1583","ADC","BK1515","159938","BK1574","LU1815336091.USD","BK1161","BL","BK4080","III","159839"],"gpt_icon":0},{"id":"2516456126","title":"277億元！A股“醫藥一哥”2024年業績大增55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516456126","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516456126?lang=zh_tw&edition=fundamental","pubTime":"2025-03-02 06:03","pubTimestamp":1740866606,"startTime":"0","endTime":"0","summary":"2月27日晚间，百济神州发布2024业绩：Q4营收11亿美元，同比增长78%；全年全球总收入38亿美元，同比增长55%。泽布替尼已在在全球超过70个市场获批，2023年全球销售额达13亿美元，正式跻身“重磅炸弹”药物之列。2024年营收20亿美元，同比增长105%。研发费用研发费用方面，2024年Q4和全年研发支出分别为54万美元，195万美元，均有所增长。目前，百济神州市值达3135亿元，超越恒瑞医药市值3056亿元，成为A股的“医药一哥”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302060507a25a8fb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302060507a25a8fb9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK4139","BK4080","06160","BK4231","ADC"],"gpt_icon":0},{"id":"2514802429","title":"映恩生物二次遞表港交所，致力於癌症及免疫性疾病的ADC藥物研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2514802429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514802429?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 21:19","pubTimestamp":1740662350,"startTime":"0","endTime":"0","summary":"此前，映恩生物曾于2024年8月26日递表港交所，于2月26日失效。招股书显示，映恩生物是抗体偶联药物领域的全球领跑者，致力于为癌症和自身免疫性疾病等患者研发新一代ADC创新药物。财务方面，于2022年、2023年、2024年截至9月30日止九个月，映恩生物的收入分别约为160万元、17.87亿元、14.62亿元人民币;期内亏损分别约为3.87亿元、3.58亿元、5.66亿元人民币。","market":"hk","thumbnail":"https://static.tigerbbs.com/8701ae1b168909ce5442dde8ec02622c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8701ae1b168909ce5442dde8ec02622c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255667.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","ADC","BK4231"],"gpt_icon":1},{"id":"2514684971","title":"HER2雙抗ADC藥物JSKN003治療HER2陽性乳腺癌Ⅲ期臨牀研究完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2514684971","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514684971?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 13:21","pubTimestamp":1740633660,"startTime":"0","endTime":"0","summary":"中国苏州2025年2月27日 /美通社/ -- 康宁杰瑞生物制药与石药集团共同宣布，HER2双特异性抗体偶联药物JSKN003对比恩美曲妥珠单抗治疗HER2阳性晚期乳腺癌的Ⅲ期临床研究完成首例患者给药。HER2阳性乳腺癌是所有乳腺癌中最具侵袭性和高度恶性的亚型，近年来其诊疗格局显著改善，但复发转移性乳腺癌仍存在巨大的未满足临床需求。目前JSKN003治疗HER2低表达乳腺癌、铂耐药卵巢癌的Ⅲ期临床研究也在顺利进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4628925_ZH28925_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["09966","BK1574","BK1161","ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2514818522","title":"【首個自研ADC澳洲臨牀入組 康方生物IO 2+ADC戰略再進一步】近日，康方生物宣佈，公司自主研發的差異化靶向人表皮生長因子受體3（HER3）ADC新藥AK138D1，治療晚期惡性腫瘤的I期臨牀研究在澳洲完成首例受試者入組。AK138D1是康方生物首個進入臨牀階段的ADC藥物。ADC藥物是康方生物在全球範圍內重塑治療格局，構建腫瘤治療新標準，以創新療法造福全球患者的重要力量，也是康方生物推進“IO 2.0+ADC”戰略的重要抓手。目前康方生物自主研發的全球首創雙抗新藥卡度尼利（PD-1/CTLA-4雙抗）和依沃西（PD-1/VEGF雙抗）均已獲批上市。康方生物是全球唯一擁有2個腫瘤免疫治療雙抗的製藥公司，在IO+ADC聯合戰略中已經建立了在腫瘤免疫端的全球領先優勢。AK138D1等差異化ADC藥物的開發，為康方生物充分挖掘創新產品組合的臨牀價值，持續迭代腫瘤療法開拓了更廣闊的空間。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514818522","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514818522?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 08:40","pubTimestamp":1740616816,"startTime":"0","endTime":"0","summary":"AK138D1是康方生物首个进入临床阶段的ADC药物。ADC药物是康方生物在全球范围内重塑治疗格局，构建肿瘤治疗新标准，以创新疗法造福全球患者的重要力量，也是康方生物推进“IO 2.0+ADC”战略的重要抓手。康方生物是全球唯一拥有2个肿瘤免疫治疗双抗的制药公司，在IO+ADC联合战略中已经建立了在肿瘤免疫端的全球领先优势。AK138D1等差异化ADC药物的开发，为康方生物充分挖掘创新产品组合的临床价值，持续迭代肿瘤疗法开拓了更广阔的空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27084048415964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADC","LU0417516571.SGD","01477","LU0329678337.USD","IE00B543WZ88.USD","LU0737861772.HKD","BK1209","BK1161","BK1574","LU0348783233.USD","LU1720050803.USD","BK4080","BK4231","06078","BK1583","BK4023","LU1794554557.SGD","LU0348784397.USD","LU1169590202.USD","PD","09926","BK1191","LU0329678170.USD","LU1169589451.USD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2514242600","title":"金十數據整理：每日港股市場要聞速遞（2月26日 週三）","url":"https://stock-news.laohu8.com/highlight/detail?id=2514242600","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514242600?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:18","pubTimestamp":1740532697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4503","LU1226287875.USD","01857","YY","LU1048596156.SGD","LU1328277881.USD","LU0630378692.HKD","00522","LU0229945570.USD","LU1023057109.AUD","07226","09888","LU0197773673.USD","HUYA","YANG","HSCEI","JOYY","LU0856984785.SGD","HSTECH","BK1169","SG9999004220.SGD","BK1578","BIDU","SG9999002828.SGD","BK4514","LU0320764599.SGD","LU0640798160.USD","01876","00813","03692","LU0819121731.USD","00772","01093","LU0348735423.USD","IE00BZ08YT58.USD","BK1194","LU1813983027.USD","ADC","LU1960683339.HKD","BK1589","LU0762540952.USD","LU0821914370.USD","LU0043850808.USD","89888","LU0762541174.USD","HK0000320264.USD","LU0072462343.USD","ADC.AU","LU0326950275.SGD"],"gpt_icon":0},{"id":"2514020285","title":"康方生物依沃西攜手輝瑞ADC，國際化佈局提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020285","media":"国泰君安","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020285?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:15","pubTimestamp":1740532557,"startTime":"0","endTime":"0","summary":"2月24日，公司海外合作伙伴Summit Therapeutics宣布与辉瑞达成临床试验合作，有望深入挖掘依沃西联合辉瑞多款vedotin系列ADCs药物联合疗法在多种实体瘤中的巨大潜力。辉瑞为全球ADC领域头部玩家，有望提供丰富产品组合。多项临床布局推动下，依沃西有望在肺癌领域实现全线布局，与ADC的联合给药有望在长期进一步带来治疗模式的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226093052a2541cfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226093052a2541cfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","BK4533","BK4534","LU0289739699.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","BK4585","BK4581","LU0306806265.USD","SG9999001176.USD","BK4592","IE000M9KFDE8.USD","LU1066051498.USD","SG9999001176.SGD","IE00BLSP4239.USD","LU0306807586.USD","BK4568","SG9999002232.USD","SG9999013999.USD","LU1023059063.AUD","LU1057294990.SGD","IE00B19Z3581.USD","BK4550","BK4588","LU1066053197.SGD","LU0225771236.USD","SG9999003800.SGD","SG9999011175.SGD","LU0985481810.HKD","LU0225284248.USD","SG9999002224.SGD","LU1894683348.USD","BK4599","LU0170899867.USD","LU0321505868.SGD","LU1894683264.USD","LU0234572021.USD","PFE","LU0058720904.USD","IE0002270589.USD","SGXZ57979304.SGD","BK4231","ADC","BK4007","LU1883839398.USD","IE00BBT3K403.USD","LU0456855351.SGD","LU0122379950.USD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2514021200","title":"【券商聚焦】交銀國際維持康方生物(09926)買入評級 指PD-1雙抗+ADC聯用潛力值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2514021200","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514021200?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 08:59","pubTimestamp":1740531544,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康方生物 依沃西将与辉瑞公司多个ADCs药物开展联合疗法临床试验：2月24日， Summit Therapeutics 宣布与辉瑞达成临床试验合作，共同推进 PD1/VEGF 双抗依沃西与辉瑞多款vedotin ADC 在多种实体瘤中的联合治疗应用。辉瑞将全面负责临床试验的开展及相关费用，Summit将提供依沃西并参与海外研究。初步临床结果显示，PD-1靶向药物能与vedotin ADC形成协同效应。该行维持买入评级和87港元目标价，并继续将公司选为行业重点推荐标的之一。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1953886","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","PD","ADC"],"gpt_icon":0},{"id":"2514011721","title":"Nuvation Bio Inc.盤中異動 股價大跌5.29%報1.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514011721?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 00:32","pubTimestamp":1740501159,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时32分，Nuvation Bio Inc.股票出现异动，股价快速下挫5.29%。截至发稿，该股报1.97美元/股，成交量130.438万股，换手率0.39%，振幅5.53%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226003239a253a26d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226003239a253a26d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","BK4007","ADC","NUVB","BK4212","BK4231","DDC"],"gpt_icon":0},{"id":"2514018325","title":"藥明合聯與LigaChem Biosciences簽署合作備忘錄，加速ADC開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018325","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514018325?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 18:25","pubTimestamp":1740479100,"startTime":"0","endTime":"0","summary":"LigaChem Biosciences是开发抗体偶联药物疗法以攻克癌症及其他重大疾病的行业先锋，此次新协议的签署标志着双方合作进一步扩大，有助于加速下一代ADC疗法的研发进程。根据合作备忘录，药明合联一体化ADC药物发现平台将助力LigaChem Biosciences大幅提升其ADC研发项目的速度与效率。关于 LigaChem Biosciences LigaChem Biosciences致力于发现和开发抗体偶联药物治疗癌症和其他严重疾病的创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4626686_ZH26686_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","02268","BK1141","ADC","BK4231","SG9999014674.SGD","BK4080"],"gpt_icon":0},{"id":"2514105716","title":"一款明星HER-2 ADC夢碎時","url":"https://stock-news.laohu8.com/highlight/detail?id=2514105716","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514105716?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 16:39","pubTimestamp":1740472764,"startTime":"0","endTime":"0","summary":"横空出世的DS-8201，改变了很多药企的轨迹，正如明星biotech Ambrx那样。2022年10月，Ambrx主动宣布暂停了ARX788的研发工作。核心原因在于，HER-2 ADC药物的市场格局发生了变化。DS-8201上市之后，能不能打得过霸主，成了诸多HER-2 ADC必须回答的一个问题。这一研究旨在曲妥珠单抗耐药的HER-2 乳腺癌患者中，评估ARX788与拉帕替尼加卡培他滨的疗效差异。随着DS-8201不断交出碾压性的临床数据，HER-2 ADC后来者的命运也随之发生改变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251594","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2514182705","title":"Nuvation Bio Inc.盤中異動 急速下跌5.20%報2.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514182705","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514182705?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 04:57","pubTimestamp":1740430666,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时57分，Nuvation Bio Inc.股票出现波动，股价急速跳水5.20%。截至发稿，该股报2.10美元/股，成交量151.362万股，换手率0.45%，振幅5.88%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.40%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045746abdb5e44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045746abdb5e44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4212","ADC","NUVB","BK4007","BK4080","DDC","BK4231"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2025-05-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-13","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-13"},{"date":"2025-04-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-30","defaultRemindTime":1746019800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-04-30","currency":"USD","dateTimestamp":1745985600000,"payDate":"2025-05-14"},{"market":"US","date":"2025-04-22","symbol":"ADC","fiscalQuarterEnding":"2025/03","expectedEps":1.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1745294400000,"reportTimeType":"post","actualEps":1.06},{"date":"2025-03-31","symbol":"ADC","amount":0.253,"announcedDate":"2025-03-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-14","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-14"},{"date":"2025-02-28","symbol":"ADC","amount":0.253,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-14","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-14","value":0.465,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-13","value":0.465,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2016-01-05","value":0.465,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.4286,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":21,"updateTime":1746676800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2025-05-23","current":42.755537,"percent":0.651749,"low":31.539495,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"high":53.261716,"avg":41.115349,"sd":4.473929,"marketCap":8180587826},"quantilePoints":[{"date":"2020-05-29","current":40.87144,"twenty":30.127131,"median":35.446997,"eighty":42.650816,"marketCap":3390817259},{"date":"2020-06-05","current":44.67404,"twenty":30.209273,"median":35.585113,"eighty":42.788104,"marketCap":3706292371},{"date":"2020-06-12","current":43.306667,"twenty":30.259415,"median":35.631973,"eighty":42.882133,"marketCap":3592850978},{"date":"2020-06-19","current":43.938263,"twenty":30.399208,"median":35.674606,"eighty":42.926676,"marketCap":3645250098},{"date":"2020-06-26","current":40.969109,"twenty":30.470777,"median":35.744304,"eighty":42.989446,"marketCap":3398920216},{"date":"2020-07-02","current":43.619209,"twenty":30.497525,"median":35.833506,"eighty":43.024146,"marketCap":3618780439},{"date":"2020-07-10","current":41.587683,"twenty":30.543737,"median":35.93098,"eighty":43.037844,"marketCap":3450238941},{"date":"2020-07-17","current":42.77274,"twenty":30.603622,"median":36.099734,"eighty":43.037844,"marketCap":3548554815},{"date":"2020-07-24","current":37.537078,"twenty":30.71291,"median":36.149452,"eighty":43.037844,"marketCap":3365424257},{"date":"2020-07-31","current":40.350852,"twenty":30.745133,"median":36.199495,"eighty":43.037844,"marketCap":3617696027},{"date":"2020-08-07","current":41.351038,"twenty":30.776927,"median":36.250246,"eighty":43.037844,"marketCap":3707368648},{"date":"2020-08-14","current":40.224323,"twenty":30.922362,"median":36.348523,"eighty":43.037844,"marketCap":3606351900},{"date":"2020-08-21","current":40.308676,"twenty":31.08368,"median":36.544296,"eighty":43.037844,"marketCap":3613914651},{"date":"2020-08-28","current":40.628012,"twenty":31.203975,"median":36.640352,"eighty":43.037844,"marketCap":3642545066},{"date":"2020-09-04","current":40.013441,"twenty":31.296906,"median":36.781594,"eighty":43.037844,"marketCap":3587445022},{"date":"2020-09-11","current":40.079718,"twenty":31.383772,"median":36.974643,"eighty":43.037844,"marketCap":3593387184},{"date":"2020-09-18","current":38.59149,"twenty":31.509762,"median":37.052903,"eighty":43.037844,"marketCap":3459958646},{"date":"2020-09-25","current":37.645532,"twenty":31.534039,"median":37.273263,"eighty":43.037844,"marketCap":3375147794},{"date":"2020-10-02","current":39.29644,"twenty":31.704694,"median":37.362034,"eighty":43.037844,"marketCap":3523161638},{"date":"2020-10-09","current":40.368928,"twenty":31.803276,"median":37.497873,"eighty":43.037844,"marketCap":3619316617},{"date":"2020-10-16","current":39.386818,"twenty":31.867808,"median":37.57347,"eighty":43.037844,"marketCap":3531264585},{"date":"2020-10-23","current":40.224079,"twenty":31.975443,"median":37.612137,"eighty":43.037844,"marketCap":3633239960},{"date":"2020-10-30","current":38.164301,"twenty":31.975443,"median":37.733323,"eighty":43.037844,"marketCap":3447190528},{"date":"2020-11-06","current":38.797606,"twenty":31.975443,"median":37.935059,"eighty":43.037844,"marketCap":3504393786},{"date":"2020-11-13","current":41.26934,"twenty":31.975443,"median":38.046028,"eighty":43.037844,"marketCap":3727653105},{"date":"2020-11-20","current":40.039622,"twenty":31.975443,"median":38.167733,"eighty":43.037844,"marketCap":3616578817},{"date":"2020-11-27","current":40.506914,"twenty":31.975443,"median":38.310136,"eighty":43.037844,"marketCap":3658787046},{"date":"2020-12-04","current":40.580698,"twenty":31.975443,"median":38.471704,"eighty":43.037844,"marketCap":3665451504},{"date":"2020-12-11","current":40.230228,"twenty":31.975443,"median":38.545534,"eighty":43.037844,"marketCap":3633795331},{"date":"2020-12-18","current":39.344831,"twenty":31.975443,"median":38.676992,"eighty":43.037844,"marketCap":3553821844},{"date":"2020-12-24","current":39.762935,"twenty":31.975443,"median":38.782235,"eighty":43.037844,"marketCap":3591587102},{"date":"2020-12-31","current":40.937316,"twenty":31.975443,"median":38.892751,"eighty":43.037844,"marketCap":3697663047},{"date":"2021-01-08","current":45.450661,"twenty":31.975443,"median":39.008592,"eighty":43.047885,"marketCap":4105330986},{"date":"2021-01-15","current":44.653159,"twenty":31.975443,"median":39.245492,"eighty":43.22631,"marketCap":4033296550},{"date":"2021-01-22","current":45.359718,"twenty":31.975443,"median":39.341757,"eighty":43.313411,"marketCap":4097116533},{"date":"2021-01-29","current":44.212433,"twenty":31.975443,"median":39.41667,"eighty":43.4163,"marketCap":3993488046},{"date":"2021-02-05","current":46.262155,"twenty":31.975443,"median":39.41667,"eighty":43.554978,"marketCap":4178629185},{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826}],"updateTime":1748142467378}}}